Dilemma of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients: is Uftoral® the right answer?. (August 2014)

• Record Type: Journal Article
• Authors: Rastogi, Sameer; Sirohi, Bhawna; Deodhar, Kedar; Shetty, Nitin; Shrikhande, Shailesh V
• Is Part Of: Colorectal cancer. Volume 3:Number 4(2014)
• Page Start: 315
• Page End: 319
• Publication Date: 2014-08
• Subjects: colorectal cancer -- DPD deficiency -- fluoropyrimidines -- Uftoral® -- toxicity; Colon (Anatomy) -- Cancer -- Periodicals; Rectum -- Cancer -- Periodicals; 616.994347
• DOI: 10.2217/crc.14.27
• Languages: English
• ISSNs: 1758-194X

Abstract

SUMMARY : Fluoropyrimidines (5-fluorouracil, capecitabine, S-1, Uftoral ® [UFT; Merck, Germany]) and their derivatives are effective in management of colorectal cancer. DPD deficiency is not routinely tested and is usually diagnosed after a patient has severe/grade IV toxicity secondary to the use of 5-fluorouracil or capecitabine. Once DPD deficiency is diagnosed, there are sparse data on the use of UFT or raltitrexed and there are no comparable outcome data with well-known regimens like infusional 5-fluorouracil, leucovorin oxaliplatin (FOLFOX) and infusional 5-fluorouracil, leucovorin, irinotecan (FOLFIRI). Here we report the first case series from India of DPD deficiency and the use of UFT.